IP Library Granted Patent US 10,034,942
Granted Patent B2
US 10,034,942 · App. 15/184,207 · Granted Jul 31, 2018

Stabilized hypohalous acid solutions

Inventors: Svetlana Panicheva (Downingtown, PA); Mark N. Sampson (Doylestown, PA); Vadim Panichev (Downingtown, PA); Gerald N. DiBello (West Chester, PA)
Assignee: REALM THERAPEUTICS, INC.
A61K47/02A01N25/22A01N59/00A23L3/358A61K33/10A61K33/12A61K33/14A61K33/20A61K33/42C01B11/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,034,942
App. No.
15/184,207
Granted
Jul 31, 2018
Kind
B2
Abstract

The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating and/or preserving food products and cut flowers, among other uses.

Claims (23)

1. A hydrogel formulation packaged in a container, comprising hypochlorous acid and a stabilizing amount of dissolved inorganic carbon (DIC) incorporated in the form of a bicarbonate or carbonate salt of an alkali or alkaline earth metal,

wherein the hydrogel formulation has an available free chlorine (AFC) content of from about 100 to about 1,000 parts per million, a pH of from 4.4 to 7.0, a ratio of DIC to AFC of from 2:1 to 1:2, and a silicate-containing carrier of from about 0.5% to about 5%,

and wherein the container is nonpermeable to CO 2 or O 2 .

2. The hydrogel formulation of claim 1 , wherein the silicate-containing carrier is sodium magnesium fluorosilicate.

3. The hydrogel formulation of claim 1 , wherein said AFC content is from about 100 to about 500 parts per million.

4. The hydrogel formulation of claim 1 , wherein the formulation has an electro-conductivity of from about 0.5 mS/cm to about 12 mS/cm.

5. The hydrogel formulation of claim 1 , wherein said pH is from 5 to 7.

6. The hydrogel formulation of claim 1 , wherein the DIC is added to the hypochlorous acid as sodium bicarbonate.

7. The hydrogel formulation of claim 6 , wherein the amount of sodium bicarbonate is about equimolar with the AFC content.

8. The stabilized solution or formulation of claim 1 , wherein the hypochlorous acid is prepared by electrolysis of a NaCl solution.

9. The hydrogel formulation of claim 8 , wherein the DIC is sodium bicarbonates and is added after electrolysis.

10. The hydrogel formulation of claim 1 , wherein the container is plastic.

11. A method for disinfecting or treating a mammalian tissue, the method comprising applying a hydrogel formulation to a mammalian tissue in need of disinfection or treatment; the formulation comprising hypochlorous acid and a stabilizing amount of dissolved inorganic carbon (DIC) incorporated in the form of a bicarbonate or carbonate salt of an alkali or alkaline earth metal,

wherein the hydrogel formulation has an available free chlorine (AFC) content of from about 100 to about 1.000 parts per million, a DH of from 4.4 to 7.0, a ratio of DIC to AFC of from 2:1 to 1:2, and a silicate-containing carrier of from about 0.5% to about 5%.

12. The method of claim 11 , wherein the mammalian tissue is infected or comprises a wound or burn.

13. The method of claim 11 , wherein the hydrogel formulation is applied to an affected area of a mammal having inflammation.

14. The method of claim 13 , wherein the inflammation is a hyper inflammation of the skin.

15. The method of claim 11 , wherein the hydrogel formulation is applied to an affected area of a mammal having dermatoses.

16. The method of claim 15 , wherein the hydrogel formulation is applied to an affected area of a mammal having atopic dermatitis, skin allergy, rosacea, psoriasis, or acne.

17. The method of claim 16 , wherein the hydrogel formulation is applied to an affected area of a mammal having atopic dermatitis.

18. The method of claim 16 , wherein the hydrogel formulation is applied to an affected area of a mammal having psoriasis.

19. The method of claim 16 , wherein the hydrogel formulation is applied to an affected area of a mammal having skin allergy.

20. The method of claim 16 , wherein the hydrogel formulation is applied to an affected area of a mammal having acne.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: REALM THERAPEUTICS, INC.
To: URGO US, INC.
Reel/Frame 049405/0191 →
CHANGE OF NAME Recorded Jan 5, 2017
From: PURICORE, INC.
To: REALM THERAPEUTICS, INC.
Reel/Frame 041268/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2016
From: PANICHEVA, SVETLANA; SAMPSON, MARK N.; PANICHEV, VADIM; DIBELLO, GERALD N.
To: PURICORE, INC.
Reel/Frame 038933/0883 →
Continuity (5)
Continuation 14501977 · Sep 30, 2014
Continuation 13423822 · Mar 19, 2012
Provisional Application 61454383 · Mar 18, 2011
Provisional Application 61526149 · Aug 22, 2011
Related Publication 20170014512A1 · Jan 19, 2017